欧洲1型自身免疫性胰腺炎:临床特征与治疗反应
该研究回顾性分析了42家欧洲大学医院自2005年以来诊断的735例1型或未特指型自身免疫性胰腺炎(AIP)成人患者,评估现有治疗方案的有效性。激素治疗组625例的完全缓解率为79%、部分缓解率18%、累积缓解率97%;未治疗组95例的完全缓解率61%、部分缓解率19%、累积缓解率80%。高剂量(≥0.4 mg/kg/天)与低剂量(<0.4 mg/kg/天)激素疗效无显著差异,IgG4升高与完全缓解几率降低独立相关。
要点
- 激素治疗组完全缓解率79%(496/625),未治疗组完全缓解率61%(58/95)。
- 高剂量(≥0.4 mg/kg/天)与低剂量(<0.4 mg/kg/天)激素疗效无显著差异(OR 0.428,95%CI 0.054-3.387)。
- IgG4升高与完全缓解几率降低独立相关(OR 0.639,95%CI 0.427-0.955)。
核心结论
- IgG4水平升高的1型AIP患者可能需要更密切的监测。
- 对于诱导缓解,起始剂量0.4 mg/kg/天持续2周后短期减量似乎有效。
- 本研究未提供证据支持更激进的方案。
研究设计与样本
- 回顾性分析2005年以来在42家欧洲大学医院诊断的成人1型或未特指型AIP患者。
- 采用统一诊断标准诊断1型AIP,排除2型AIP及接受胰腺手术者。
- 共纳入735例患者,男性占69%,中位年龄57岁,白人占85%。
主要发现
- 激素治疗组634例中9例(1%)失访,其余625例完全缓解率79%(496/625)、部分缓解率18%(111/625)、累积缓解率97%(607/625)、未缓解率3%(18/625)。
- 未治疗组95例完全缓解率61%(58/95)、部分缓解率19%(18/95)、累积缓解率80%(76/95)。
- 高剂量(≥0.4 mg/kg/天)与低剂量(<0.4 mg/kg/天)激素疗效无显著差异(OR 0.428,95%CI 0.054-3.387)。
- 起始剂量持续时间>2周与≤2周相比疗效无显著差异(OR 0.908,95%CI 0.818-1.009)。
- IgG4升高与完全缓解几率降低独立相关(OR 0.639,95%CI 0.427-0.955)。
临床怎么用
- 作者认为,IgG4水平升高的1型AIP患者可能需要更密切的监测。
- 作者认为,诱导缓解可采用起始剂量0.4 mg/kg/天持续2周后短期减量,似乎有效。
- 本研究未提供证据支持更激进的方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Autoimmune pancreatitis (AIP) is an immune-mediated disease of the pancreas with distinct pathophysiology and manifestations. Our aims were to characterize type 1 AIP in a large pan-European cohort and study the effectiveness of current treatment regimens. METHODS: We retrospectively analyzed adults diagnosed since 2005 with type 1 or not-otherwise-specified AIP in 42 European university hospitals. Type 1 AIP was uniformly diagnosed using specific diagnostic criteria. Patients with type 2 AIP and those who had undergone pancreatic surgery were excluded. The primary end point was complete remission, defined as the absence of clinical symptoms and resolution of the index radiologic pancreatic abnormalities attributed to AIP. RESULTS: We included 735 individuals with AIP (69% male; median age, 57 years; 85% White). Steroid treatment was started in 634 patients, of whom 9 (1%) were lost to follow-up. The remaining 625 had a 79% (496/625) complete, 18% (111/625) partial, and 97% (607/625) cumulative remission rate, whereas 3% (18/625) did not achieve remission. No treatment was given in 95 patients, who had a 61% complete (58/95), 19% partial (18/95), and 80% cumulative (76/95) spontaneous remission rate. Higher (≥0.4 mg/kg/day) corticosteroid doses were no more effective than lower (<0.4 mg/kg/day) doses (odds ratio, 0.428; 95% confidence interval, 0.054-3.387) and neither was a starting dose duration >2 weeks (odds ratio, 0.908; 95% confidence interval, 0.818-1.009). Elevated IgG4 levels were independently associated with a decreased chance of complete remission (odds ratio, 0.639; 95% confidence interval, 0.427-0.955). Relapse occurred in 30% of patients. Relapses within 6 months of remission induction were independent of the steroid-tapering duration, induction treatment duration, and total cumulative dose. CONCLUSIONS: Patients with type 1 AIP and elevated IgG4 level may need closer monitoring. For remission induction, a starting dose of 0.4 mg/kg/day for 2 weeks followed by a short taper period seems effective. This study provides no evidence to support more aggressive regimens.
引用
- Overbeek KA, Poulsen JL, Lanzillotta M, et al. Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment. Clin Gastroenterol Hepatol. 2024. PMID: 38184096. doi:10.1016/j.cgh.2023.12.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。